RecruitingInterventional

Assessing the Impact of a Web-based Educational Program on the Sexual Health Outcomes of Young Adult Female Cancer Survivors ~ A Pilot Trial

NCT ID: NCT06868121Sponsor: University of ChicagoLast updated: 2026-06-05

Summary

The purpose of this study is to assess the impact of the web-based intervention OMGYES.com on sexual dysfunction in young adult (YA) female-bodied cancer survivors. This pilot trial seeks to evaluate the intervention's: * feasibility * acceptability * appropriateness. Researchers will utilize an active observation period to compare outcomes between those receiving the intervention immediately and those who haven't Participants will: * Complete online modules at home * Visit the clinic every 5 weeks for questionnaires

Arms & interventions

OtherOMGYES.com
OMGYES.com is an interactive website that offers information, video tutorials, interviews, tips, and resources to explore female sexual pleasure through groundbreaking research that's told through the real-life experiences of women of all ages and life stages.

Outcome measures

Primary

Feasibility of OMGYES.com using the Feasibility of Intervention Measure (FIM)
The Feasibility of Intervention Measure (FIM) is a validated questionnaire that utilizes a 5-point Likert scale to evaluate the extent at which an intervention can be successfully used in a clinical setting.
Time frame: End of Study (Week 6)

Secondary

Acceptability of OMGYES.com using the Acceptability of Intervention Measure (AIM)
Time frame: End of Study (Week 6)
Appropriateness of OMGYES.com using the Appropriateness of Intervention Measure
Time frame: End of Study (Week 6)

Eligibility criteria

Sex: FemaleAge: 18 Years to 45 YearsHealthy volunteers: No

Inclusion Criteria: * Age 18 to 45 years * Diagnosis of cancer between the ages of 15 and 45 * Female genitalia, regardless of gender * Diagnosed with sexual dysfunction * Complete Remission and at least two months from a major treatment * Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial * Ability to participate in study modules and to respond to surveys * Ability to understand and the willingness to sign a written informed consent document Exclusion Criteria: * Patients receiving other investigational agents * Patients expected to be neutropenic or have a significantly high infection risk that would exclude them from vaginal penetration * Patients who are unable complete the study intervention or surveys

Study locations (1)

University of Chicago Hospital

Chicago, Illinois, 60637

Recruiting

Adam DuVall, MD · Principal Investigator